Intellia Therapeutics selects Dr. John Leonard as new CEO

Intellia Therapeutics, a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology, promoted John Leonard, MD, to president and CEO, effective Jan. 1, 2018.

Advertisement

Dr. Leonard, who has worked at Intellia since 2014, currently serves as the company’s executive vice president of research and development. He previously served as Intellia’s CMO.

Dr. Leonard came to Intellia from AbbVie, a global biopharmaceutical company, where he was chief scientific officer and senior vice president of research and development.

Dr. Leonard succeeds Nessan Bermingham, PhD, Intellia’s founding president and CEO, who is leaving for the venture capital arena.

More articles on health IT:
FCC approves measure to dismantle net neutrality in 3-2 vote
FTC issues privacy warning over direct-to-consumer genetic tests
Allscripts CEO Paul Black talks McKesson acquisition, 2018 goals: 6 questions

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.